How One Sponsor Achieved IND Clearance for a First-in-Human Trial

Background: The Investigational Product and Sponsor Profile

This case study highlights a mid-sized biotechnology company preparing to enter clinical trials with a novel small-molecule kinase inhibitor. The molecule was developed to treat relapsed/refractory acute myeloid leukemia (AML) and showed strong preclinical efficacy across multiple cell lines and animal models.

With limited internal regulatory resources and a tight development timeline, the sponsor partnered with a global regulatory consultancy to plan, prepare, and submit the Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA).

To benchmark global trial standards, the team also reviewed historical data and protocols on platforms like ClinicalTrials.gov.

Key Objective: Initiate a Safe and Compliant First-in-Human Study

The company’s goal was to gain FDA clearance for a Phase 1, first-in-human (FIH) dose-escalation study in adult patients with AML. This entailed preparing robust:

• Nonclinical pharmacology and toxicology data
• Chemistry, Manufacturing, and Controls (CMC) documentation
• A scientifically justified and risk-mitigated clinical protocol

A key challenge was ensuring that the starting dose was safe yet scientifically meaningful — without triggering a clinical hold.

Timeline and Strategy

The project was executed over a 9-month timeline:

• Month 1–3: Data gap analysis and development planning
• Month 4–6: Conduct of GLP toxicology studies and CMC process scale-up
• Month 7: Pre-IND meeting request and preparation
• Month 8: Finalization of IND modules
• Month 9: eCTD publishing and submission

Pre-IND Meeting Highlights

The sponsor held a Type B Pre-IND meeting with the FDA 60 days prior to submission. Key topics discussed included:

• Acceptability of 28-day toxicology data from rats and dogs
• Stability data required for a 12-week trial duration
• Proposed starting dose and escalation scheme

The FDA agreed in principle with the development plan but requested clarification on cardiac safety and hERG data, which the sponsor promptly addressed.

Sample Table: Nonclinical Toxicology Summary

IND Submission, FDA Review, and Trial Launch

Final IND Submission Package: Key Inclusions

The final IND submission included the following:

• Module 1: FDA Forms 1571 and 1572, Cover Letter, IRB documentation
• Module 2: Overall summaries for quality, nonclinical, and clinical
• Module 3: Drug substance and drug product data, process controls, stability
• Module 4: Full study reports of pharmacology, TK/PK, genotoxicity, and 28-day toxicity
• Module 5: Draft clinical protocol, investigator brochure, clinical monitoring plan

eCTD publishing was performed using validated commercial tools. Prior to uploading via the FDA ESG, the submission was run through the agency’s validation criteria checklist to ensure formatting and metadata compliance.

FDA Review Outcome

The FDA completed its 30-day review without issuing a clinical hold. However, the agency sent an Information Request (IR) asking for:

• Clarification on analytical method validation for assay accuracy
• Justification for dose escalation intervals

The sponsor responded within 5 business days with detailed data tables, redlined protocol updates, and analytical certificates.

FDA confirmed IND activation on Day 29, allowing the trial to initiate as planned.

Early Clinical Trial Success and Learning

The first patient was dosed within 45 days of IND clearance. The clinical team used a standard 3+3 dose escalation design with intensive safety monitoring, including cardiac telemetry, liver function testing, and daily vitals.

By the third dosing cohort, early signs of biological activity were observed, supporting further dose expansion in subsequent trial phases.

Key Lessons Learned from the IND Process

• Early gap analysis of nonclinical data saved critical time during finalization
• Engaging the FDA early helped prevent major CMC or protocol redesign later
• Strong project management was key to aligning cross-functional contributors
• Clear documentation and consistent formatting ensured a smooth review

Case Impact and Broader Application

The successful clearance of this IND allowed the sponsor to raise additional Series B funding, initiate patient enrollment across four U.S. sites, and submit a parallel CTA in Canada.

The strategy, tools, and team structure used in this case were later replicated across two additional INDs for other oncology programs within the same company.

Conclusion: A Roadmap for IND Success

This case study demonstrates that a well-executed IND submission — grounded in scientific integrity, robust planning, and regulatory engagement — can lead to smooth FDA clearance, rapid trial initiation, and long-term program momentum.

Whether you’re a small biotech or a multinational sponsor, success begins with early preparation, clear communication, and structured documentation. With these foundations, your first-in-human IND can be more than just a submission — it can be a launchpad for innovation.

Comparing Initial and Expanded Access INDs: Purpose, Process, and Key Regulatory Differences

Introduction: What Is an IND and Why Are There Different Types?

An Investigational New Drug (IND) application allows sponsors to legally administer an unapproved drug to humans. While most INDs are submitted to initiate clinical trials (initial INDs), the U.S. Food and Drug Administration (FDA) also provides a mechanism called Expanded Access IND — commonly referred to as “compassionate use” — for patients with serious or life-threatening conditions who lack other treatment options.

Understanding the differences between initial and expanded access INDs is critical for clinical researchers, regulatory professionals, and healthcare providers seeking investigational treatment outside of a formal trial setting.

Sponsors frequently consult global databases like ANZCTR to track investigational use programs and eligibility standards in other regions.

What Is an Initial IND?

The Initial IND, often called a “commercial IND,” is submitted by sponsors to begin clinical trials of an investigational drug. The purpose is to generate safety and efficacy data that can support a future marketing application.

An initial IND must include:

• Nonclinical pharmacology and toxicology data
• Chemistry, Manufacturing, and Controls (CMC) information
• A complete clinical trial protocol
• Investigator brochures and regulatory forms

The FDA reviews initial INDs within 30 days to determine if the proposed trial may proceed or if a clinical hold is necessary.

What Is an Expanded Access IND?

The Expanded Access IND (EA-IND) permits the use of an investigational drug outside of a clinical trial, usually for a single patient, intermediate-size population, or treatment group. These programs are designed for patients with serious or life-threatening conditions who cannot enroll in a trial and have no satisfactory alternatives.

EA-INDs are generally non-commercial and focus on individual patient treatment rather than drug development.

Three Categories of Expanded Access

• Single-Patient IND: For an individual patient, often under emergency use
• Intermediate-Size IND: For a group of patients with the same condition
• Treatment IND: For widespread access during late-stage development

Regulatory Requirements: Initial vs Expanded Access IND

While both types of INDs require safety oversight, there are important differences in submission content and review timelines.

Sample Table: Comparison of Initial and Expanded Access INDs

Submission Pathways, Documentation, and Compliance Tips

Submission Process for Initial INDs

Initial INDs must follow the full CTD structure with modules for administrative forms, summaries, quality, nonclinical and clinical data. Key documents include:

• FDA Form 1571 (application form)
• Form 1572 (investigator statement)
• Clinical protocol and investigator brochure
• CMC and toxicology reports

Sponsors must submit in electronic Common Technical Document (eCTD) format via the FDA’s Electronic Submissions Gateway (ESG).

Submission Process for Expanded Access INDs

EA-INDs, especially for single-patient use, have simplified submission requirements. In emergency situations, the sponsor may obtain verbal authorization from the FDA followed by a written submission within 15 days.

Required documents typically include:

• FDA Form 3926 (streamlined form for individual patients)
• Informed consent documentation
• Letter of authorization from the drug manufacturer
• Clinical rationale and treatment plan

IRB approval is also required unless exempted due to urgency.

Ethical and Safety Oversight

Regardless of IND type, the FDA requires that the investigational product is administered under adequate safety monitoring and ethical oversight. Sponsors must:

• Report serious adverse events (SAEs) within mandated timelines
• Submit annual reports for ongoing INDs
• Ensure data integrity and patient protection

For EA-INDs, adverse events must be reported under 21 CFR 312.32, and follow-up reports may be requested if the use extends beyond a single dose.

When to Use Which Pathway?

The decision between an initial IND and an expanded access IND depends on the goal:

• Use an initial IND when conducting a formal study to support drug development or marketing authorization
• Use an expanded access IND when treating an individual patient with no clinical trial options

Both require FDA approval, but the intent and regulatory burden differ significantly.

Case Example: Expanded Access for a Rare Pediatric Disease

A pediatric neurologist submitted a single-patient EA-IND for a child with a rare genetic disorder unresponsive to approved therapies. The investigational product had shown early promise in Phase 1 trials, but the patient was not eligible due to age restrictions.

The sponsor submitted Form 3926, IRB approval, manufacturer’s authorization, and treatment plan. FDA approval was granted within 48 hours under emergency use provisions. Treatment commenced, and safety data were later integrated into the sponsor’s development program.

Conclusion: Making the Right IND Choice

Initial and Expanded Access INDs serve very different but equally important roles in the U.S. drug development and access ecosystem. While initial INDs drive innovation through structured clinical trials, expanded access INDs ensure that patients facing life-threatening conditions can obtain investigational treatments when no other options exist.

Regulatory teams must understand the procedural, ethical, and strategic considerations of both types. With proper planning, documentation, and adherence to FDA guidelines, both pathways can be used effectively to advance clinical research and patient care.

Preparing for a Successful Pre-IND Meeting with the FDA

Introduction to Pre-IND Meetings

A Pre-Investigational New Drug (Pre-IND) meeting is one of the most valuable opportunities for sponsors to engage with the FDA early in the drug development process. Classified as a Type B meeting, it enables sponsors to align their nonclinical, clinical, and Chemistry, Manufacturing, and Controls (CMC) plans with FDA expectations before submitting an IND application.

The objective is to de-risk the IND submission by obtaining feedback on data gaps, clinical protocol design, and regulatory concerns. While Pre-IND meetings are not mandatory, they are strongly encouraged—especially for novel molecules, complex products, or first-in-human (FIH) studies.

Regulatory professionals frequently consult international regulatory portals such as India’s Clinical Trials Registry (CTRI) to understand how similar investigational products were planned and approved.

When Should You Request a Pre-IND Meeting?

Sponsors typically request a Pre-IND meeting 6–12 months prior to submitting their IND. This timing allows enough flexibility to:

• Incorporate FDA feedback into the development plan
• Complete additional nonclinical studies if required
• Revise the clinical protocol or CMC data

The ideal timing depends on your program’s complexity. For high-risk drugs such as gene therapies or cytotoxic agents, early interaction is critical.

Requesting the Meeting: Key Requirements

Sponsors must submit a formal meeting request to the appropriate FDA division. The request should include:

• Proposed meeting format (teleconference, written response, or face-to-face)
• Rationale for the meeting
• A list of proposed questions
• Timeline of development activities

The FDA typically responds within 21 calendar days, confirming whether the meeting is granted and specifying the date (usually 60 days from acceptance).

Preparing the Briefing Package

The briefing package is the foundation of the meeting and must be submitted no later than 30 days before the scheduled meeting. It must be clear, concise, and structured to enable efficient FDA review.

The standard contents of a briefing package include:

• Executive Summary
• Product description and mechanism of action
• Summary of completed and planned nonclinical studies
• Overview of CMC, including formulation and stability data
• Draft clinical protocol or study synopsis
• Specific, numbered questions for FDA input

Sample Table: Pre-IND Questions Format

Strategic Tips for an Effective Pre-IND Meeting

Simply securing a Pre-IND meeting isn’t enough — the goal is to extract meaningful feedback. Consider these best practices:

• Prioritize high-impact questions over low-value administrative ones
• Use cross-functional teams to prepare answers to anticipated FDA queries
• Keep briefing documents under 100 pages, unless justified
• Use standard CTD module formats for ease of review

Meeting Execution and Post-Meeting Actions

Conducting the Meeting: Roles and Responsibilities

Pre-IND meetings are typically held as teleconferences. The meeting is led by the FDA project manager, and attendees may include nonclinical, clinical, and CMC reviewers.

The sponsor team should include a regulatory lead, subject matter experts, and a designated note-taker. Key roles include:

• Regulatory Lead: Drives agenda and manages time
• Clinical Lead: Answers protocol-related questions
• CMC Lead: Addresses manufacturing and formulation queries

The sponsor should rehearse the meeting in advance, including potential follow-up questions. It’s also wise to prepare contingency slides or data to address unanticipated concerns.

FDA Responses: Interpreting and Using the Feedback

The FDA will issue official meeting minutes within 30 days, which become part of the regulatory record. These minutes will reflect:

• The FDA’s responses to each submitted question
• Clarifications or follow-ups discussed during the meeting
• Agreements or disagreements on trial design and data plans

Sponsors should not assume verbal comments override written responses. Regulatory actions must be based on documented FDA positions.

Addressing Gaps and Follow-Up Actions

Based on the meeting outcomes, sponsors may need to:

• Conduct additional safety studies
• Revise the clinical protocol or dosing plan
• Update CMC controls or release specifications

For instance, if the FDA recommends a lower starting dose, the sponsor should update the protocol and justify changes in the IND cover letter.

Integrating Pre-IND Feedback into the IND Package

Incorporating FDA feedback improves the quality and reviewability of the final IND. When submitting the IND, sponsors should include a section summarizing how each Pre-IND comment was addressed.

This shows responsiveness, regulatory maturity, and risk-based thinking — key values that FDA reviewers appreciate. It may also reduce the likelihood of a clinical hold.

Global Perspective: Similar Meetings in Other Jurisdictions

Many countries have equivalent mechanisms for early regulatory interaction. Examples include:

• EU (EMA): Scientific Advice Meeting
• Japan (PMDA): Consultation Meetings
• Canada (Health Canada): Pre-CTA Meetings

These processes vary in formality but serve the same purpose — aligning on data expectations and minimizing regulatory risk.

For comparative insights, sponsors may consult databases like ANZCTR (Australia & New Zealand Clinical Trials Registry).

Conclusion: Leveraging the Pre-IND Meeting for Regulatory Success

A Pre-IND meeting is more than a procedural step — it is a strategic engagement that can shape the trajectory of a drug development program. Thoughtfully preparing the briefing package, asking the right questions, and fully leveraging FDA insights can significantly improve IND quality and reduce review timelines.

Sponsors should treat the Pre-IND meeting as an opportunity to demonstrate scientific readiness, regulatory diligence, and commitment to patient safety. When executed correctly, this meeting becomes a foundational moment in successful IND planning and clinical trial authorization.